| Darapladib |
|
| (CAS 356057-34-6) |
 |
| Description： |
Darapladib is a selective and orally active inhibitor of Lp-PLA2 (IC50= 270 pM)
IC50 value: 270 pM
Target: Lp-PLA2
Darapladib, is a novel inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that may link lipid metabolism with inflammation, leading to the increased stability of atherosclerotic plaques present in the major arteries. Darapladib is being studied as a possible add-on treatment for atherosclerosis.
|
| Product No. |
KT20883 |
| Product Name |
Darapladib |
| Synonyms |
|
| Formal Name |
|
| CAS Number |
356057-34-6 |
| Molecular Formula |
C36H38F4N4O2S |
| Formula Weight |
|
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
CAY10650
CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM.
IC50 value: 12 nM
Target: cPLA2
CAY10650 is a highly potent (IC50 = 12 nM) cPLA2α inhibitor. It demonstrates strong anti-inflammatory effects when applied topically at a dose of 0.1 mg/ear in a mouse model of acute irritant contact dermatitis. Chinese hamsters (n = 6/group) were infected with parasite-laden contact lenses and treated with cPLA2α inhibitors (AACOCF3 and CAY10650) 50 μg/5 μl was injected with topical eye-drop under the contact lens of an infected cornea three times a day for 6 days and topically on days 7–14 postinfection. Animals were anesthetized and sacrificed 15 days after application of cPLA2α inhibitors. Treatment with the AACOCF3 and CAY10650 had a profound effect on the severity and chronicity of keratitis. In addition, hamsters treated with AACOCF3 had significantly less severe keratitis as compared with CAY10650 group.
|
|
